782493-64-5 Usage
General Description
Tert-butyl 4-(4-(ethoxycarbonyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate is a specific chemical compound with a complex molecular structure. It contains a tert-butyl group, a piperidine ring, and a pyrazol-1-yl group, as well as an ethoxycarbonyl moiety. tert-butyl 4-(4-(ethoxycarbonyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate is commonly used in organic synthesis and medicinal chemistry, where it may be utilized as a building block for the preparation of pharmaceuticals and other biologically active molecules. Its unique structure and functional groups make it a valuable intermediate in the synthesis of various compounds with potential therapeutic applications. Tert-butyl 4-(4-(ethoxycarbonyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate is of interest to researchers and chemists due to its versatile reactivity and potential for the development of novel drug candidates.
Check Digit Verification of cas no
The CAS Registry Mumber 782493-64-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,8,2,4,9 and 3 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 782493-64:
(8*7)+(7*8)+(6*2)+(5*4)+(4*9)+(3*3)+(2*6)+(1*4)=205
205 % 10 = 5
So 782493-64-5 is a valid CAS Registry Number.
782493-64-5Relevant articles and documents
INHIBITORS OF SARM1
-
Paragraph 0274; 0277-0278, (2020/12/30)
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF
-
Paragraph 0618-0619, (2019/05/15)
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
GLYCOSIDASE INHIBITORS
-
, (2017/09/15)
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
